Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function (EMPIRE)
Primary Purpose
Colon Cancer
Status
Completed
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
Omegaven
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Colon Cancer focused on measuring fish oil, omega-3 fatty acids, postoperative inflammatory response, erythrocyte function
Eligibility Criteria
Inclusion Criteria:
- Patients (male or female) undergoing elective laparoscopic surgery for colon cancer
- Age between 60 and 80 years
- BMI between 20 kg/m2 and below 30 kg/m2
- Written informed consent
Exclusion Criteria:
- Participation in or having participated in another clinical trial within the previous 3 months
- Indications for continuously use of anticoagulant medication and no possibility to stop these medication perioperatively, for example patients with an artificial heart valve
- Pre-operative Hemoglobin<5.0 mmol/L
- Metastatic disease
- Very poor peripheral venous access
- Current history of inflammatory or infectious disease
- The use of anti-inflammatory drugs
- The use of thyroid medication
- The use of fish oil products or fish consumption more than 2 times a week
- Contra-indication for the use of Omegaven-Fresenius, including:
- General contra-indications for parenteral nutrition
- Allergy to fish or egg protein.
Sites / Locations
- Medical Center of Alkmaar
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
Omegaven
Arm Description
2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
Outcomes
Primary Outcome Measures
Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood
Ex vivo stimulation of whole blood with LPS (lipopolysaccharide, component of gram negative bacteria) resulting in the production of the pro-inflammatory cytokine IL-6, measured in ng/ml.
Secondary Outcome Measures
Change in ex vivo production of TNF-α and IL-10 in LPS stimulated whole blood
Ex vivo stimulation of whole blood with LPS (lipopolysaccharide, component of gram negative bacteria) resulting in the production of the pro-inflammatory cytokine TNF-α (tumor necrosis factor-α), and the anti-inflammatory cytokine IL-10 (interleukine-10), both measured in ng/ml.
Change in erythrocyte function
Erythrocyte deformability and aggregation measured by LORRCA (laser assisted optical rotational red cell analyzer)
Change in in vivo systemic inflammatory response parameters
White blood cell count, C-reactive protein and cytokine levels (Interleukine-6, Tumor Necrosis Factor-α and Interleukine-10) in serum.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02231203
Brief Title
Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function
Acronym
EMPIRE
Official Title
Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
October 2014 (Actual)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical Center Alkmaar
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Ideally, the postoperative inflammatory response is part of a well-orchestrated mechanism that contributes to tissue healing and rapid recovery. An exaggerated uncontrolled inflammatory response, however may lead to catabolism, tissue damage and organ failure. Omega-3 fatty acids may provide a means to alter cellular immune responses to the benefit of the patient. When omega-3 fatty acids are incorporated into membranes of inflammatory cells, they trigger intracellular signalling pathways that result in a less pro-inflammatory response. They modify gene and protein expression, modulate membrane protein activity and act as a reservoir for bioactive molecules. They also have a strong anti-inflammatory effect by mediating resolution of the inflammation. Furthermore, omega-3 fatty acids improve erythrocyte function, which is vital for an adequate microcirculation, tissue oxygenation and wound healing.
The investigators hypothesize that the perioperative administration of intravenous omega-3 fatty acids results in a rapid incorporation in immune cells and erythrocytes, thereby reducing the postoperative inflammatory response and improving erythrocyte function in patients undergoing colorectal surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colon Cancer
Keywords
fish oil, omega-3 fatty acids, postoperative inflammatory response, erythrocyte function
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
44 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
Arm Title
Omegaven
Arm Type
Active Comparator
Arm Description
2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
Intervention Type
Drug
Intervention Name(s)
Omegaven
Other Intervention Name(s)
purified fish oil, omega-3 fatty acids, eicosapentaenoicacid (EPA), docosahexaenoicacid (DHA), dl-a- tocopherol (antioxidant), Omegaven-Fresenius
Intervention Description
2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
NaCl 0,9%, Natriumchloride 0,9%, glass container NaCl 0,9% Fresenius Kabi
Intervention Description
2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Primary Outcome Measure Information:
Title
Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood
Description
Ex vivo stimulation of whole blood with LPS (lipopolysaccharide, component of gram negative bacteria) resulting in the production of the pro-inflammatory cytokine IL-6, measured in ng/ml.
Time Frame
baseline, day of surgery, postoperative day 1,2 and 4
Secondary Outcome Measure Information:
Title
Change in ex vivo production of TNF-α and IL-10 in LPS stimulated whole blood
Description
Ex vivo stimulation of whole blood with LPS (lipopolysaccharide, component of gram negative bacteria) resulting in the production of the pro-inflammatory cytokine TNF-α (tumor necrosis factor-α), and the anti-inflammatory cytokine IL-10 (interleukine-10), both measured in ng/ml.
Time Frame
baseline, day of surgery, postoperative day 1, 2 and 4
Title
Change in erythrocyte function
Description
Erythrocyte deformability and aggregation measured by LORRCA (laser assisted optical rotational red cell analyzer)
Time Frame
baseline, day of surgery, postoperative day 1, 2 and 4
Title
Change in in vivo systemic inflammatory response parameters
Description
White blood cell count, C-reactive protein and cytokine levels (Interleukine-6, Tumor Necrosis Factor-α and Interleukine-10) in serum.
Time Frame
baseline, day of surgery, postoperative day 1, 2 and 4
Other Pre-specified Outcome Measures:
Title
Postoperative outcome (composite measure of length of stay and complications)
Description
Length of hospital stay and occurence of surgical site infection, abscess, urinary tract infection, pneumonia, anastomotic leakage, need for Intensive Care Unit admission, Systemic Inflammatory Response Syndrome, Multi Organ Failure, any adverse events.
Time Frame
Registration during admission, follow up 2 and 4 weeks after surgery
Title
Cognitive function
Description
Neuropsychological examination using a reading test, an auditory verbal learning test, WAIS III figure series and trail making tests.
Time Frame
baseline, follow up 2 weeks after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients (male or female) undergoing elective laparoscopic surgery for colon cancer
Age between 60 and 80 years
BMI between 20 kg/m2 and below 30 kg/m2
Written informed consent
Exclusion Criteria:
Participation in or having participated in another clinical trial within the previous 3 months
Indications for continuously use of anticoagulant medication and no possibility to stop these medication perioperatively, for example patients with an artificial heart valve
Pre-operative Hemoglobin<5.0 mmol/L
Metastatic disease
Very poor peripheral venous access
Current history of inflammatory or infectious disease
The use of anti-inflammatory drugs
The use of thyroid medication
The use of fish oil products or fish consumption more than 2 times a week
Contra-indication for the use of Omegaven-Fresenius, including:
General contra-indications for parenteral nutrition
Allergy to fish or egg protein.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
A.P.J. Houdijk, Dr.
Organizational Affiliation
Medical Center of Alkmaar
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Center of Alkmaar
City
Alkmaar
State/Province
Noord Holland
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
31826232
Citation
Bakker N, van den Helder RS, Stoutjesdijk E, van Pelt J, Houdijk APJ. Effects of perioperative intravenous omega-3 fatty acids in colon cancer patients: a randomized, double-blind, placebo-controlled clinical trial. Am J Clin Nutr. 2020 Feb 1;111(2):385-395. doi: 10.1093/ajcn/nqz281.
Results Reference
derived
Learn more about this trial
Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function
We'll reach out to this number within 24 hrs